BioCryst Pharmaceuticals Cash on Hand 2010-2025 | BCRX

BioCryst Pharmaceuticals cash on hand from 2010 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
BioCryst Pharmaceuticals Annual Cash on Hand
(Millions of US $)
2024 $321
2023 $391
2022 $426
2021 $511
2020 $303
2019 $138
2018 $106
2017 $118
2016 $56
2015 $53
2014 $73
2013 $38
2012 $36
2011 $42
2010 $55
2009 $70
BioCryst Pharmaceuticals Quarterly Cash on Hand
(Millions of US $)
2025-03-31 $295
2024-12-31 $321
2024-09-30 $331
2024-06-30 $274
2024-03-31 $338
2023-12-31 $391
2023-09-30 $399
2023-06-30 $412
2023-03-31 $400
2022-12-31 $426
2022-09-30 $428
2022-06-30 $419
2022-03-31 $447
2021-12-31 $511
2021-09-30 $204
2021-06-30 $223
2021-03-31 $244
2020-12-31 $303
2020-09-30 $146
2020-06-30 $192
2020-03-31 $115
2019-12-31 $138
2019-09-30 $70
2019-06-30 $97
2019-03-31 $110
2018-12-31 $106
2018-09-30 $122
2018-06-30 $88
2018-03-31 $96
2017-12-31 $118
2017-09-30 $165
2017-06-30 $86
2017-03-31 $101
2016-12-31 $56
2016-09-30 $54
2016-06-30 $40
2016-03-31 $38
2015-12-31 $53
2015-09-30 $72
2015-06-30 $96
2015-03-31 $70
2014-12-31 $73
2014-09-30 $127
2014-06-30 $132
2014-03-31 $32
2013-12-31 $38
2013-09-30 $43
2013-06-30 $31
2013-03-31 $29
2012-12-31 $36
2012-09-30 $41
2012-06-30 $37
2012-03-31 $44
2011-12-31 $42
2011-09-30 $45
2011-06-30 $59
2011-03-31 $69
2010-12-31 $55
2010-09-30 $61
2010-06-30 $56
2010-03-31 $64
2009-12-31 $70
2009-09-30 $35
2009-06-30 $42
2009-03-31 $54
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.720B $0.451B
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $81.683B 31.42
Zoetis (ZTS) United States $66.251B 24.72
Daiichi Sankyo, - (DSNKY) Japan $46.431B 23.80
Takeda Pharmaceutical (TAK) Japan $43.274B 8.83
BeOne Medicines - (ONC) Cayman Islands $32.874B 0.00
Sandoz Group AG (SDZNY) Switzerland $25.885B 0.00
Summit Therapeutics (SMMT) United States $19.799B 0.00
Merck (MKKGY) Germany $16.472B 12.07
Shionogi (SGIOY) Japan $14.326B 14.35
Neurocrine Biosciences (NBIX) United States $13.535B 40.46
United Therapeutics (UTHR) United States $12.718B 11.01
Orion OYJ (ORINY) Finland $11.482B 27.67
IPSEN (IPSEY) France $10.802B 0.00
Stevanato Group S.p.A (STVN) Italy $7.553B 46.19
Grifols, S.A (GRFS) Spain $7.460B 0.00
Corcept Therapeutics (CORT) United States $7.414B 60.27
Ionis Pharmaceuticals (IONS) United States $6.903B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.436B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.853B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.214B 15.86
Soleno Therapeutics (SLNO) United States $4.277B 0.00
Hypermarcas (HYPMY) Brazil $3.066B 20.17
Crinetics Pharmaceuticals (CRNX) United States $2.737B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.596B 9.09
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.529B 13.68
NewAmsterdam Pharma (NAMS) Netherlands $2.518B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.213B 0.00
Ocular Therapeutix (OCUL) United States $1.857B 0.00
Endo (NDOI) United States $1.763B 0.00
ARS Pharmaceuticals (SPRY) United States $1.756B 0.00
Evotec AG (EVO) Germany $1.481B 0.00
Dyne Therapeutics (DYN) United States $1.410B 0.00
Guardian Pharmacy Services (GRDN) United States $1.296B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.223B 24.46
Harrow (HROW) United States $1.199B 0.00
Ardelyx (ARDX) United States $1.038B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.035B 0.00
Collegium Pharmaceutical (COLL) United States $0.986B 5.32
Akebia Therapeutics (AKBA) United States $0.961B 0.00
Enliven Therapeutics (ELVN) United States $0.948B 0.00
Xeris Biopharma Holdings (XERS) United States $0.802B 0.00
ProKidney (PROK) United States $0.787B 0.00
Cronos Group (CRON) Canada $0.771B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.710B 0.00
KalVista Pharmaceuticals (KALV) United States $0.691B 0.00
Relay Therapeutics (RLAY) United States $0.622B 0.00
Xencor (XNCR) United States $0.621B 0.00
Zevra Therapeutics (ZVRA) United States $0.601B 0.00
Tourmaline Bio (TRML) United States $0.600B 0.00
Organogenesis (ORGO) United States $0.591B 0.00
Elite Pharmaceuticals (ELTP) United States $0.563B 0.00
Theravance Biopharma (TBPH) United States $0.554B 0.00
USANA Health Sciences (USNA) United States $0.550B 11.06
Oruka Therapeutics (ORKA) United States $0.516B 0.00
Siga Technologies (SIGA) United States $0.477B 9.96
Savara (SVRA) United States $0.442B 0.00
Aquestive Therapeutics (AQST) United States $0.389B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.376B 10.15
AleAnna (ANNA) United States $0.347B 0.00
Nanobiotix S.A (NBTX) France $0.315B 0.00
Aldeyra Therapeutics (ALDX) United States $0.302B 0.00
Altimmune (ALT) United States $0.296B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.284B 0.00
Esperion Therapeutics (ESPR) United States $0.279B 0.00
Nektar Therapeutics (NKTR) United States $0.274B 0.00
Heron Therapeutics (HRTX) United States $0.273B 0.00
Nature's Sunshine Products (NATR) United States $0.266B 24.42
OmniAb (OABI) United States $0.238B 0.00
Larimar Therapeutics (LRMR) United States $0.229B 0.00
Galectin Therapeutics (GALT) United States $0.228B 0.00
MediWound (MDWD) Israel $0.209B 0.00
4D Molecular Therapeutics (FDMT) United States $0.204B 0.00
Lyell Immunopharma (LYEL) United States $0.184B 0.00
China SXT Pharmaceuticals (SXTC) China $0.178B 0.00
Journey Medical (DERM) United States $0.177B 0.00
Liminatus Pharma (LIMN) United States $0.176B 0.00
Profound Medical (PROF) Canada $0.167B 0.00
Aclaris Therapeutics (ACRS) United States $0.166B 0.00
Lexeo Therapeutics (LXEO) United States $0.154B 0.00
Korro Bio (KRRO) United States $0.153B 0.00
Avita Medical (RCEL) United States $0.142B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.135B 0.00
Protara Therapeutics (TARA) United States $0.123B 0.00
Inhibikase Therapeutics (IKT) United States $0.123B 0.00
Cardiol Therapeutics (CRDL) Canada $0.122B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.113B 0.00
Innate Pharma SA (IPHYF) France $0.110B 0.00
Cassava Sciences (SAVA) United States $0.104B 0.00
Achieve Life Sciences (ACHV) Canada $0.093B 0.00
Fractyl Health (GUTS) United States $0.089B 0.00
Champions Oncology (CSBR) United States $0.088B 20.03
Metagenomi (MGX) United States $0.085B 0.00
Vivani Medical (VANI) United States $0.085B 0.00
VAXART, INC (VXRT) United States $0.084B 0.00
ESSA Pharma (EPIX) Canada $0.083B 0.00
Surrozen (SRZN) United States $0.080B 0.00
Nutriband (NTRB) United States $0.079B 0.00
Arch Biopartners (ACHFF) Canada $0.078B 0.00
PMV Pharmaceuticals (PMVP) United States $0.074B 0.00
Context Therapeutics (CNTX) United States $0.073B 0.00
Avalo Therapeutics (AVTX) United States $0.072B 0.00
Pyxis Oncology (PYXS) United States $0.071B 0.00
Inotiv (NOTV) United States $0.071B 0.00
Wellgistics Health (WGRX) United States $0.069B 0.00
Assertio Holdings (ASRT) United States $0.067B 0.00
Rafael Holdings (RFL) United States $0.065B 0.00
Dominari Holdings (DOMH) United States $0.065B 0.00
DURECT (DRRX) United States $0.059B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Telomir Pharmaceuticals (TELO) United States $0.058B 0.00
Unicycive Therapeutics (UNCY) United States $0.056B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.055B 0.00
ElectroCore (ECOR) United States $0.052B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.051B 38.22
Century Therapeutics (IPSC) United States $0.049B 0.00
NRx Pharmaceuticals (NRXP) United States $0.049B 0.00
Jupiter Neurosciences (JUNS) United States $0.047B 0.00
Prelude Therapeutics (PRLD) United States $0.046B 0.00
Klotho Neurosciences (KLTO) United States $0.046B 0.00
Gain Therapeutics (GANX) United States $0.045B 0.00
Acrivon Therapeutics (ACRV) United States $0.041B 0.00
Mural Oncology (MURA) Ireland $0.040B 0.00
Enlivex Therapeutics (ENLV) Israel $0.036B 0.00
PolyPid (PYPD) Israel $0.035B 0.00
Karyopharm Therapeutics (KPTI) United States $0.035B 0.00
Iterum Therapeutics (ITRM) Ireland $0.032B 0.00
FibroGen (FGEN) United States $0.028B 0.00
Tempest Therapeutics (TPST) United States $0.028B 0.00
Plus Therapeutics (PSTV) United States $0.028B 0.00
SCYNEXIS (SCYX) United States $0.027B 0.00
Vivos Therapeutics (VVOS) United States $0.027B 0.00
Incannex Healthcare (IXHL) Australia $0.026B 0.00
Cosmos Health (COSM) United States $0.026B 0.00
Scienture Holdings (SCNX) United States $0.025B 0.00
Natural Alternatives (NAII) United States $0.022B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.022B 0.00
Relmada Therapeutics (RLMD) United States $0.021B 0.00
Lipocine (LPCN) United States $0.018B 0.00
Mannatech (MTEX) United States $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.016B 0.00
Citius Pharmaceuticals (CTXR) United States $0.015B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
Minerva Neurosciences (NERV) United States $0.013B 2.33
TherapeuticsMD (TXMD) United States $0.013B 0.00
BioVie (BIVI) United States $0.012B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
Ainos (AIMD) United States $0.011B 0.00
TransCode Therapeutics (RNAZ) United States $0.009B 0.00
Lyra Therapeutics (LYRA) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Aptorum Group (APM) United Kingdom $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Talphera (TLPH) United States $0.009B 0.00
Traws Pharma (TRAW) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
VYNE Therapeutics (VYNE) United States $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Qualigen Therapeutics (QLGN) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
SHINECO (SISI) China $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Aditxt (ADTX) United States $0.002B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Indivior (INDV) United States $0.000B 10.18
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00